Trial reportArteriosclerosis, thrombosis, and vascular biology2019
Group IIA Secretory Phospholipase A
Trial report in Arteriosclerosis, thrombosis, and vascular biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 33 citations in OpenAlex.
- One-Year Effects of High-Intensity Statin on Bioactive Lipids: Findings From the JUPITER Trial.Arteriosclerosis, thrombosis, and vascular biology · 2024Trial
- Anti-Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial.Journal of the American Heart Association · 2020 · on this mapTrial
- The Phospholipase AJournal of lipid and atherosclerosis · 2026Review
- Association ofBiomedical reports · 2026Article
- N-Glycosylation Profiles of Immunoglobulin G and Future Cardiovascular Events.Circulation research · 2024Article
- Identification of an Allele-Specific Transcription Factor Binding Interaction that May Regulate PLA2G2A Gene Expression.Bioinformatics and biology insights · 2024Article
- Mechanistic exploration of Yiqi Liangxue Shengji prescription on restenosis after balloon injury by integrating metabolomics with network pharmacology.Pharmaceutical biology · 2023Article
- The Link between Prostanoids and Cardiovascular Diseases.International journal of molecular sciences · 2023Review
- Genetically personalised organ-specific metabolic models in health and disease.Nature communications · 2022Article
- Review
- What do secreted phospholipases ABiochimie · 2021Review
- An Updated Review of Pro- and Anti-Inflammatory Properties of Plasma Lysophosphatidylcholines in the Vascular System.International journal of molecular sciences · 2020Review
- Secreted Phospholipase ACells · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 3 countries.
Funding
Abstract
Objective- Inflammation is a causal risk factor for cardiovascular disease (CVD). sPLA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.